Studie

An Open-label, Single Arm, Multicenter Study to Broaden Access to Emapalumab, an Anti-Interferon Gamma (Anti-IFNγ) Monoclonal Antibody, and to Assess its Efficacy, Safety, Impact on Quality of Life, and Long-term Outcome in Pediatric Patients with Primary

Erkrankungsgruppe:

Lymphome

Organsystem:

Immunsystem, Lymphsystem

Stadium:

Therapierefraktär

Standort:

Essen

EudraCT:

2017-003114-10

Prüfplan-Code:

NI-0501-09

Phase:

III

Prüfsubstanz:

Emapalumab

Sponsor:

Swedish Orphan Biovitrum AG